Sharekhan

Cohance Lifesciences Ltd

Mon 24/11/2025,15:59:13 NSE: COHANCE

₹ 569.80 -19.50 (-3.31%)
BUY NOW Buy Cohance Lifesciences Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Cohance Lifesciences Ltd

Mon 24/11/2025,16:1:0

Cohance Lifesciences Ltd

Mon 24/11/2025,15:59:13 | NSE : COHANCE

₹ 569.80-19.50 (-3.31%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 587.00

Previous Close

₹ 589.30

Volume

748723

Mkt Cap ( Rs. Cr)

₹21798.68

High

₹ 587.00

Low

₹ 565.20

52 Week High

₹ 1360.00

52 Week Low

₹ 573.80

Book Value Per Share

₹ 44.68

Dividend Yield

0.00

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Cohance Lifesciences Ltd

Your Vote -

Buy

61.54%

Hold

23.08%

Sell

15.38%

61.54%

13 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

569.80

64

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

64

Option Chain

Analyzes market sentiment, predicts Cohance Lifesciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    17 Nov 2025, 7:44PM Con Call Transcript

  • Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    17 Nov 2025, 7:41PM Cohance Lifesciences Limited has informed the Exchange about Transcript

  • Cohance Lifesciences - Copy of Newspaper Publication

    14 Nov 2025, 2:37PM Cohance Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication

  • Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    12 Nov 2025, 10:24PM Audio of conference call

  • Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    12 Nov 2025, 10:21PM Cohance Lifesciences Limited has informed the Exchange about Link of Recording

  • Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Investor Presentation

    12 Nov 2025, 6:57PM Investor Presentation

  • Cohance Lifesciences - Investor Presentation

    12 Nov 2025, 6:55PM Cohance Lifesciences Limited has informed the Exchange about Investor Presentation

  • Cohance Lifesciences Q2 net profit up 23.53% at Rs 94.29 cr

    12 Nov 2025, 6:43PM The company reported standalone net profit of Rs 94.29 crore for the quarter ended September 30, 2025 as compared to Rs 76.33 crore in the same period

  • Cohance Lifesciences - Outcome of Board Meeting

    12 Nov 2025, 6:41PM Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.

  • Cohance Lifesciences - Outcome Of The Meeting

    12 Nov 2025, 6:37PM Outcome of the meeting

  • Cohance Lifesciences - Board Meeting Outcome for Outcome Of The Board Meeting

    12 Nov 2025, 6:31PM Outcome of the Board Meeting

  • Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    5 Nov 2025, 7:56PM Cohance Lifesciences Limited has informed the Exchange about Schedule of the results conference call

  • Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    5 Nov 2025, 7:51PM Results Conference Call

  • Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    5 Nov 2025, 7:47PM Schedule of the Meet

  • Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    5 Nov 2025, 7:42PM Cohance Lifesciences Limited has informed the Exchange about Schedule of meet

  • Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    1 Nov 2025, 4:57PM Cohance Lifesciences Limited has informed the Exchange about Transcript

  • Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    1 Nov 2025, 5:02PM Transcript

  • Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    28 Oct 2025, 8:57PM Cohance Lifesciences Limited has informed the Exchange about Link of Recording

  • Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    28 Oct 2025, 8:56PM Conference Call Audio

  • Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Change in Directorate

    28 Oct 2025, 6:06PM Change in Directors

  • Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    28 Oct 2025, 6:02PM Schedule of Conference Call for Investors and analysts

  • Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    28 Oct 2025, 6:00PM Cohance Lifesciences Limited has informed the Exchange about Schedule of meet

  • Cohance Lifesciences - Change in Director(s)

    28 Oct 2025, 5:49PM Cohance Lifesciences Limited has informed the Exchange regarding Change in Director(s) of the company.

  • Cohance Lifesciences - General Update

    26 Oct 2025, 6:05PM General Update

  • Cohance Lifesciences - General Updates

    26 Oct 2025, 6:04PM Cohance Lifesciences Limited has informed the Exchange about General Updates

  • Cohance Lifesciences has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025

    16 Oct 2025, 7:50PM As of September 2025, 57.49% is owned by Foreign Promoters and 42.51% by Public. <p align=justify> Institutional holds 27.32% (Insurance Companies 3.9

  • Cohance Lifesciences - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Oct 2025, 12:01PM Cohance Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Cohance Lifesciences - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    8 Oct 2025, 12:02PM Compliance Certificate under reg. 74(5) of SEBI (DP) Regulations

  • Cohance Lifesciences - Trading Window

    27 Sep 2025, 11:22PM Cohance Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulati

  • Cohance Lifesciences - Board Meeting Intimation for Considering And Approval Of The Unaudited Financial Results (Standalone A

    27 Sep 2025, 11:16PM Cohance Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider

  • Cohance Lifesciences - Copy of Newspaper Publication

    24 Sep 2025, 3:58PM Cohance Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication

  • Cohance Lifesciences - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    19 Sep 2025, 7:50PM Scrutinizer`s report for 7th Annual General Meeting

  • Cohance Lifesciences - Shareholders meeting

    19 Sep 2025, 7:45PM Cohance Lifesciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 19, 2025. Further, the compan

  • Cohance Lifesciences - Shareholder Meeting / Postal Ballot-Outcome of AGM

    19 Sep 2025, 7:45PM Outcome of the 7th Annual General Meeting.

  • Cohance Lifesciences - General Updates

    18 Sep 2025, 11:38PM Cohance Lifesciences Limited has informed the Exchange about clarification on reported news in electronic media

  • Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    18 Sep 2025, 11:03PM Investor meet

  • Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    18 Sep 2025, 11:03PM Cohance Lifesciences Limited has informed the Exchange about Schedule of meet

  • Cohance Lifesciences - General Updates

    18 Sep 2025, 7:27PM Cohance Lifesciences Limited has informed the Exchange about disclosure under SEBI PIT Regulations

  • Cohance Lifesciences - Disclosure Under SEBI PIT Regulations

    18 Sep 2025, 7:27PM Disclosure under SEBI PIT Regulations

  • Cohance Lifesciences - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    19 Sep 2025, 7:50PM Scrutinizer`s report for 7th Annual General Meeting

  • Cohance Lifesciences - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    19 Sep 2025, 7:50PM Scrutinizer`s report for 7th Annual General Meeting

  • Cohance Lifesciences - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    19 Sep 2025, 7:50PM Scrutinizer`s report for 7th Annual General Meeting

  • Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    15 Sep 2025, 3:27PM Cohance Lifesciences Limited has informed the Exchange about Schedule of meet

  • Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    15 Sep 2025, 3:17PM Investors Meet

  • USFDA Completes cGMP Audit of Cohance Lifesciences&rsquo; API Facility in Andhra Pradesh with Zero Observations

    11 Sep 2025, 6:48PM Cohance Lifesciences Ltd announced that the United States Food and Drug Administration (USFDA) has successfully completed a current Good Manufacturing

  • Cohance Lifesciences - General Updates

    11 Sep 2025, 6:09PM Cohance Lifesciences Limited has informed the Exchange about Completion of USFDA Inspection

  • Cohance Lifesciences - Completion Of USFDA Inspection

    11 Sep 2025, 6:09PM Completion of USFDA Inspection

  • Cohance Lifesciences - Letter To Shareholders Regarding Annual Report

    28 Aug 2025, 4:13PM Letter to shareholders regarding Annual Report

  • Cohance Lifesciences - General Updates

    28 Aug 2025, 4:12PM Cohance Lifesciences Limited has informed the Exchange about Letter to Shareholders regarding Annual Report

  • Cohance Lifesciences - Updates

    27 Aug 2025, 4:52PM Cohance Lifesciences Limited has informed the Exchange regarding 'Disclosure under the SEBI (Prohibition of Insider Trading) Regulations, 2015'.

  • Cohance Lifesciences - Copy of Newspaper Publication

    27 Aug 2025, 4:06PM Cohance Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication

  • Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    27 Aug 2025, 3:54PM Cohance Lifesciences Limited has informed the Exchange about Schedule of meet

  • Cohance Lifesciences - Credit Rating

    27 Aug 2025, 3:41PM Cohance Lifesciences Limited has informed the Exchange about Credit Rating

  • Cohance Lifesciences - General Announcement

    27 Aug 2025, 4:53PM Disclosure under the SEBI (Prohibition of Insider Trading) Regulations, 2015

  • Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    27 Aug 2025, 3:55PM Investors Meet

  • Cohance Lifesciences - Announcement under Regulation 30 (LODR)-Credit Rating

    27 Aug 2025, 3:42PM Credit Rating

  • Cohance Lifesciences - Business Responsibility and Sustainability Reporting (BRSR)

    26 Aug 2025, 11:08PM BRSR 2025

  • Cohance Lifesciences - Reg. 34 (1) Annual Report.

    26 Aug 2025, 11:02PM Annual Report for FY 2024-25

  • Cohance Lifesciences - Shareholders meeting

    26 Aug 2025, 10:56PM Cohance Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 19, 2025

  • Cohance Lifesciences - Notice Of AGM

    26 Aug 2025, 10:55PM Notice of 7th Annual General Meeting to be held on September 19, 2025

  • Suven Pharmaceuticals

    23 Dec 2024 , 12:39PM The drugmaker acquired 56% stake in US-based NJ Bio Inc. for $64.4 million. (Rs. 533 crore)

  • Suven Pharmaceutical up on to buy stake in Hyderabad based CDMO

    14 Jun 2024 , 11:35AM Shares of Suven Pharmaceuticals rose by 5.65% to Rs. 705, as the company is going to acquire stake in Sapala Organics

  • Suven Pharmaceuticals

    26 Feb 2024 , 10:27AM Active Pharmaceutical Ingredients and Formulations facilities (Unit-3 and Unit-5, respectively) in Pashamylaram completed the Pre-Approval Inspections (PAI) and Good Manufacturing Practices (GMP) inspections by the US Food & Drug Administration. The inspection was conducted from February 12, 2024, to February 23, 2024, and no Form 483 has been issued as a result of the inspection. (Positive).

  • Suven Pharma gets nod from Chemical & Fertilizer Ministry for acquisition.

    26 Sep 2023 , 12:27PM Suven Pharma receives approval from Chemical & Fertilizer Ministry for acquisition of up to 76.1% stake in co by Berhyanda

  • Suven Pharma

    26 Dec 2022 , 11:24AM Suven Pharma is being bought out entirely by Advent International. Advent’s offer has been accepted by Suven’s board. Blackstone was another contender for the same. Promoters Venkateswarlu Jasti and his family own 60% of the company. Advent will buy 51% of the promoter’s stake in the company and launch an open offer for an additional 26%. Advent is expected to pay close to Friday’s market price of Rs 500/share - Rs 504/share to buy the promoter’s stake, implying a payout of Rs 6,350 crore. Depending on the open offer, the final deal size could cross Rs. 8,100 Cr. This entails an EV/EBITDA multiple of 14x Suven’s LTM EBITDA, which is in line with the deals in the pharma space. Positive.

  • Advent to acquire significant stake in Suven Pharma

    26 Dec 2022 , 9:46AM Advent International to acquire a significant stake in Suven Pharmaceuticals from the Jasti family

  • Suven Pharma USFDA completes inspection of Casper Unit

    4 Oct 2022 , 1:25PM Casper Pharma Receives EIR from USFDA for its PAI

  • Suven Pharmaceuticals

    1 Aug 2022 , 10:00AM Suven Pharmaceuticals: The USFDA has completed the pre-approval inspection at wholly owned subsidiary - Casper Pharma’s formulations manufacturing facility at Hyderabad. The facility was inspected between 25th July to 29th July 2022 and the inspection ended with no observations being issued, which is positive, though we don’t have any coverage on the stock

  • Suven Pharma to acquire Hyderabad-based formulation co Casper Pharma for Rs 155. cr

    5 Apr 2022 , 2:19PM Suven Pharma board approves the investments by way of purchase of entire (100%) share capital from the existing shareholders of Casper Pharma

  • Suven Pharmaceuticals trades strong

    24 Mar 2022 , 12:29PM Shares of Suven Pharmaceuticals rises nearly 5% to Rs. 617

  • Suven Pharmaceuticals enters into agreement with CSIR

    11 Jun 2021 , 2:49PM CSIR-IICT and SUVEN Pharmaceutical, joined hands for the process technology transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG

  • Suven Pharma

    11 Jun 2021 , 9:16AM Suven Pharma: The company has entered in to an MOU arrangement with CSIR-Indian Institute of Chemical Technology (IICT) Hyderabad and CSIR-National Institute of Interdisciplinary Science & Technology for the process technology transfer and manufacturing of the anti-Covid drug, Molnupiravir. The antiviral drug was initially developed to treat influenza and is repurposed to completely suppress the Covid virus transmission with in 24 hours. This is positive for Suven as the demand for the drug could be higher given the higher Covid cases in the country

  • Suven Pharmaceuticals

    27 Apr 2020 , 12:39PM As per media reports a massive fire has been reported at pharma research and manufacturing company in Telangana (Hyderabad). The fire was in the building of Suven Pharmaceuticals Ltd in Jeediemtla Area.
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Cohance Lifesciences Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 2385.55 2094.4715 1818.5426 1616.2667 1206.4118
Liabilities 2385.55 2094.4715 1818.5426 1616.2667 1206.4118
Equity 25.46 25.4565 25.4565 25.4565 25.4565
Gross Profit 362.57 409.8999 583.0776 579.9883 440.5217
Net Profit 271.71 304.8161 432.6025 558.0988 308.6469
Cash From Operating Activities 301.03 370.6473 484.1702 269.8946 329.7266
NPM(%) 24.84 29.73 32.52 42.27 30.56
Revenue 1093.51 1024.9932 1330.0798 1320.2221 1009.7185
Expenses 730.94 615.0933 747.0022 740.2338 569.1968
ROE(%) 15.89 17.83 25.3 32.64 18.05

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
09 Sep 2022 5 500 0 491.1
09 Sep 2022 1 100 0 468.7
13 May 2022 1 100 0 586
15 Feb 2022 2 200 0 551.45
15 Feb 2022 1 100 0 538.35
13 Aug 2021 1 100 0 496.45
17 Feb 2021 1 100 0 480.15

Peers

Other companies within the same industry or sector that are comparable to Cohance Lifesciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 780.40 -0.84 0.00 335.95 301.39 0.64
Lotus Eye Hospital and Institute Ltd 105.00 -0.57 328.13 1224.17 3.55 0.00
Vaishali Pharma Ltd 9.11 -3.80 0.00 7679.65 3.13 0.00
Astec Lifesciences Ltd 890.00 7.36 0.00 1154.42 -604.77 0.00

Company Info

The Company was incorporated as a public limited company under the Companies Act, 2013, in Hyderabad, Telangana,India, pursuant to a certificate of incorporation dated November 6, 2018 issued by the Registrar of Companies,Telangana, at Hyderabad. 2020 -Suven Pharmaceuticals Ltd. has issued Bonus Shares in the Ratio of 1:1. 2021 -CSIR-IICT and SUVEN Pharmaceuticals Ltd., joined hands for the process technology transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG. 2022 -Advent to acquire significant stake in Suven Pharmaceuticals from Jasti family. -Suven Pharmaceuticals approves acquisition of Casper Pharma.

The Company was incorporated as a public limited company under the Companies Act, 2013, in Hyderabad, Telangana,India, pursuant to a certificate of incorporation dated November 6, 2018 issued by the Registrar of Companies,Telangana, at Hyderabad. 2020 -Suven Pharmaceuticals Ltd. has issued Bonus Shares in the Ratio of 1:1. 2021 -CSIR-IICT and SUVEN Pharmaceuticals Ltd., joined hands for the process technology transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG. 2022 -Advent to acquire significant stake in Suven Pharmaceuticals from Jasti family. -Suven Pharmaceuticals approves acquisition of Casper Pharma.

Read More

Parent Organisation

Cohance Lifesciences Ltd.

Founded

06/11/2018

Managing Director

Dr.V Prasada Raju

NSE Symbol

COHANCEEQ

FAQ

The current price of Cohance Lifesciences Ltd is ₹ 569.80.

The 52-week high for Cohance Lifesciences Ltd is ₹ 587.00 and the 52-week low is ₹ 565.20.

The market capitalization of Cohance Lifesciences Ltd is currently ₹ 21798.68. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Cohance Lifesciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Cohance Lifesciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Cohance Lifesciences Ltd shares.

The CEO of Cohance Lifesciences Ltd is Dr.V Prasada Raju, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT